Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

Summary

The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are: Does HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients? Participants will: Receive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.

Eligibility

Inclusion Criteria:

* Metabolic dysfunction-associated steatotic liver disease patients

Exclusion Criteria:

* Participants are unfit for hyperbaric treatment.
* Participants with prior oxygen therapy within the last 6 months.
* Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.
* Participants with severe organ dysfunctions or malignant tumors.
* Participants have weight loss plan or major operations within the last 6 months.
* Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.
* Participants are pregnant or lactating.
* Participants with claustrophobia or that cannot decompress properly.

Conditions4

Browse More Trials